阿托伐他汀对血脂正常的短暂性脑缺血发作患者颈动脉内膜-中层厚度的影响

目的观察阿托伐他汀对血脂正常的短暂性脑缺血发作(TIA)患者颈动脉内膜-中层厚度(CA-IMT)的影响。方法双盲、安慰剂对照选择42例TIA患者,随机分为阿托伐他汀组与安慰剂组,应用彩色多普勒超声测定CA-IMT,平均随访18个月,观察CA-IMT及血脂的变化。结果阿托伐他汀组的CA-IMT在0、6个月时与安慰剂组比较差异无统计学意义(P>0.05),18个月后CA-IMT较安慰剂组明显减小(P<0.05);阿托伐他汀组与安慰剂组在0、6、18个月不同时段之间的CA-IMT差异无统计学意义(P>0.05)。阿托伐他汀组6、18个月后总胆固醇(TC)、低密度脂蛋白-胆固醇(LDL-C)、甘油三酯(TG)较安慰剂组明显下降(P<0.05或<0.01),高密度脂蛋白-胆固醇(HDL-C)差异无统计学意义(P>0.05)。结论阿托伐他汀可延缓或逆转血脂相对较低的TIA患者CA-IMT的进展,18个月后明显。

Effect of atorvastatin on intima media thickness of the carotid artery in transient ischemic attack patients with normal cholesterol

Objective To investigate if atorvastatin is effective in reducing carotid intima media thickness (CA-IMT) in normocholesterolaemic patients with transient ischemic attack (TIA). Methods Forty-two patients with TIA were recruited. Patients were randomised to receive atorvastatin(5-10 mg/d) or placebo daily. Serum concentration of cholesterol and CA-IMT were measured before randomisation and at 6-and 18-month intervals. Results CA-IMT was significantly lower in atorvastatin group than that in placebo group at 18-month (P<0.05); There was no difference in CA-IMT between the two groups at 6-month. A significant reduction in total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) was observed at 6-and 18-month in patients randomised to the atorvastatin group (P<0.05 or<0.01). Conclusions The results demonstrate that atorvastatin reduces intima media thickness of the carotid artery in normocholesterolaemic patients with transient ischemic attack at 18-month.